Summary: In a double-blind, placebo-controlled study, ten chronic schizo phrenic patients with pronounced symptoms of tardive dyskinesia (TD) were withdrawn from anticholinergic medication. All patients had previously been under long-term treatment with neuroleptics and anticholinergics for at least two years. The rating-scales used were the AIMS, our own TD Scale, and the
in neuroleptic therapy, usually not observed until after two years or more. Clinically, it is characterised by involuntary, stereotyped movements, most frequently seen in the oral region (e.g. tongue protrusion and/or chewing movements).
In additon, many of the TD patients exhibit dyskinesias of the trunk (e.g. hip rocking) and of the extremities (e.g. â€˜¿ piano-playing movements' of the fingers, or â€˜¿ stamping movements' of the legs).
The pathophysiological mechanisms underlying TD are conceptualised on the basis of a hypothetical dopaminergic/cholinergic balance system in the basal ganglia. According to this hypothesis, TD corresponds to a relative predominance of the dopaminergic system, whereas neuroleptic-induced parkinsonism (pseudo-parkinsonism) corresponds to a relative cholinergic overactivity.
Hence, anticholinergic drugs can be expected to aggravate the symptoms of TD by weakening central cholinergic activity, as seen in case reports (Sovner & DiMascio, 1977; Weiss et al, 1980; Kiloh et al, 1973). Again, this assumption is strongly supported by both uncontrolled (Fann & Lake, 1974; Chouinard et a!, 1979; Klawans & Rubovits, 1974) and controlled (Gerlach & Thorsen, 1976) studies.
Less attention has been paid to the question of what happens to TD when anticholinergics are withdrawn after long-term administration.
In two previous with drawal studies, Burnett (1980) and Reunanen (1982) found a significant reduction of TI) following discontinuation of anticholinergics drugs in ten and thirteen patients respectively.
Our findings in an unpublished epiderniological study illustrate the clinical relevance of the relation ship between anticholinergic drugs and TD. In a group of 814 patients, 52% received concomitant treatment with anticholinergic medication in addition to neuro leptics. The percentage of patients receiving anti cholinergic drugs was higher amongst TD patients than amongst non-dyskinetic patients (64% vs 48%; P <.0005; chi-square statistics).
The aim of the present study was to investigate under double-blind, placebo-controlled conditions the effect of withdrawal of anticholinergic drugs on TD, after their long-term administration.
Patients and Methods
Ten patients (sevenfemalesand three males), alldiagnosed as chronic schizophrenics (ICDâ€"9 Classification of Mental Disorders), were selected for this study; Table I In addition to the BLM syndrome, all patients showed dyskinesias of the trunk or extremities (see Table II ).
The study was carried out double-blind, placebo-controlled and the investigators were not informed about the study design. The ten patients chosen were randomly assigned to two groups: Group A (n = 4) and group B (n = 6). Patients of group A received biperiden for four weeks in the same dosage as prior to the study, followed by a three-week placebo period.
Patients in Group B remained on biperiden for one week, and were then switched to placebo for six weeks.
Assessments of tardive dyskinesia and pseudo-parkinsonism were carried out weekly through the study ( Figure 1 ). All patients were ratedon biperiden and on placebo at least three times.
The dosage of neuroleptic medication remained unchanged during the study.
After the seven-week study period, each patient's doctor decided whether or not to reinstitute anticholinergic treat ment and all patients were re-examined twice during the following month under non-blind conditions. All examinationsof indi@'idual patients were carried out at the same time ofday, mainly during the late morning. Ratings were done simultaneously by the two investigators (OR, HH), the scores representing the averageof both.
Following each session, the investigators completed the Simpson-Angus scale (Simpson & Angus, 1970) for pseudo parkinsonism, the AIMS (Guy, 1976), and our own addi tional TD scale constructed on the lines laid down by Gerlach (1976) , Simpson (1979) and Heinrich (1968) . Our own TD scale was designed to assess the individual TD symptoms in more detail.
The definition of symptoms in our own study scale were derived mainly from the TD scale developed by Simpson (Rockland Scale).
The scoring used in this study scale was taken from the Gerlach scale. The individualTD symptomswere described with regard to their frequency and amplitude, both graduated from 0 to 6. The sum of these two scores was then multiplied by an intensity factor (Gerlach & Thorsen, 1976) , based on the following system: multiply constant movement by three; multiply intermittent movement by two (i.e. present more than half of the observation period), and no multiplication for occasional movements (i.e. present less than half the period of observation).
The total severity of TD was evaluated in terms of functional difficulties (e.g. difficulties in swallowing, in impairment of subtle finger movements or in walking) and psychosocial impairment (i.e. socially embarrassing, abnor mal movements).
The total score on the Simpson-Angusscale is given here without dividing it by ten, as originally described by Simpson. For statistical analysis, the mean values of the three weekly ratings preceding discontinuation of biperiden were com pared to the three ratings following its discontinuation (t-test for paired differences). Pearson's correlation coefficient was calculated for the relationship between pseudo-parkinsonism and TD.
TABLE III

Study scale'
Global evaluation of TD under biperiden (mean value of three ratings before discontinuation) and placebo (mean value of three ratings after discontinuation of biperiden) on the basis of the study scale and the AIMS; n = 10; t-test for paired differences.
â€˜¿ The four scores of the study scale and of the AIMS were highly correlated (PEARSON' correlation coefficient between r = .86and r = .90)
The changes in the mental state were documented according to the total clinical impression without using psychopathological rating scales.
Results
Nine patients completed the trial. One patient (number 10, group B) dropped out one week after biperiden withdrawal because of severe parkinsonism; in this patient, only one rating could be carried out while on the placebo.
Total assessment of TD
The effect of the discontinuation of biperiden on TD is shown in Table III . The switch to placebo resulted in a considerable improvement of the BLM syndrome and in a less pronounced reduction of trunk and extremity movements. The BLM syndrome (study scale) improved from 33.8 Â± 7.7 on biperiden to 18.2 Â±10.2 on placebo (P <.001), while the total score of trunk and extremity movements improved from 28.9 Â± 22.8 to 12.3 Â±18.5 (P <.10).
Frequency, amplitude, and the intensity factor (the three elementsof movementdisorders), all exhibited a comparable improvement.
Psycho-social impairment was significantly reduced (P <.01), and functional impairment was reduced as well, (Figure 3) . The mean value (for the five patients) rose from 17.9 Â±6.9 on placebo to 34.3 Â±19.0 on the reintroduction of biperiden.
The remaining five patients who were not prescribed anticholinergic drugs again showed a further improvement of the BLM syndrome; the mean value for these patients decreased from 18.5 Â±13.7 on placebo to 14.9 Â±12.2 in the follow-up investigations. Table IV gives an overview of the changes of the TD symptoms in different topographic regions. Only four of these symptomswere present in a sufficientnumber of patients to permit statistical analysis.
Individual TD symptoms
The most pronounced improvement after biperiden was withdrawnwasobservedin the tongue and jaw dyskinesias(P <.0001). In the five patients who were again prescribed biperiden after the end of the study, the mean values rose from 7.4 Â± 3.4 to 14.0 Â± 7.2 (tongue movements) and from 6.9 Â± 2.2 to 13.4 Â± 5.1 (jaw movements), respectively.The improvement of the remaining five patients who were not prescribed biperiden again, persisted during the follow-up period; the mean valuesdecreased from8.2 Â± 6.7 to 7.0 Â± 6.0 (tongue movements) and from 7.5 Â±4.7 to 5.4 Â±6.2 (jaw movements) respectively. A clear-cut improvement was also observed with regard to rotation/fiexion movements of the ankles (n = 7; P <.01). The dyskinetic movements of the fingers exhibited only an insignificantreduction on placebo (P <.20). For the remain ing symptoms, conclusions can hardly be drawn because of the small number of patients involved. Perioral dyskinesias and dyskinesias of the toes and the hip seemed to improve under placebo; arm and wrist movements showed no substantial changes. FIG. 2â€"Changes of the BLM-syndrome during the 7-week study-period in group A (n = 4) and in group B (n = 6 in weeks â€"¿ 1+1; â€"¿ 1 to +1;n = Sin weeks +1 to7).
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FIG. 3â€"BLM-syndrome under biperiden (mean scores of three ratings before discontinuation) and placebo (mean scores of three ratings after discontinuation of biperiden); n = 10. Broken rules: BLM-syndrome in 5 patients on biperiden again (mean scores of the follow-up examinations).
The findings on the basis of the AIMS (Table III) were essentially the same, with the exception of a significant reduction (P <.01) of trunk and extremity movements.
Course of tEl-improvement
In both group A and group B, the improvement in i'D occurred within the first two weeks after biperiden with drawal ( Figure 2 ). This improvement persisted, as could be seen in group B during a six-week placebo period.
Follow-up investigation
After the end of the study, biperiden was reintroduced in five of the ten patients. Within one month, four of these patients showed a pronounced deterioration of the BLM documented on our own study scale and on the AIMS. The reduction ofTD seemed to be more pronounced in relation to the oral dyskinesias than the limb and trunk movements, but this finding may reflect rating problems rather than a real difference. The assessment of oral dyskinesia can be worked out more easily, and they seem to be less masked by voluntary movements than are limb and trunk dyskinesias.
It could be argued that in therapeutic studies of TD, there is a general trend towards improvement, prob ably due to selection of patients which causes bias towards a favourable outcome. The severity of TI)
shows considerable spontaneous fluctuations, and in the selection of patients with pronounced symptoms, the probability of choosing an individual patient with maximum symptoms is much larger than that of one with minimum symptoms. This results in some statisti cal expectancy of improvement during investigation, regardless of the real efficacy or inefficacy of the tested agent.
In the present study, the improvement of TD appeared to be clearly related in time to withdrawal of anticholinergic drugs. Whereas in group A the switch to placebo (week 1) resulted in a reduction of TD within one or two weeks, patients in group B, who were at that time still on anticholinergic treatment, showed further aggravation of TD. When they were then switched to placebo (week 5), patients in group B showed the same prompt reduction of TD as those in group A previously. The average BLM scores of all patients(group A + group B) show a relatively con stant baseline during the three weeks before discon tinuation (34.2 Â±10.9; 34.5; 12.2; 33.8 Â±11.1); the scores in the three weeks after discontinuation (22.4 Â± 15.3; 11.8 Â±5.9 Â±18.3 Â±14.5) are all significantly lower than the baseline values (P <.025; P <.005; P <.05, compared to the last baseline value).
There are three possible explanations for the effect of withdrawal of anticholinergic drugs on tardive dyskinesia:
1. Anticholinergic medication might change the plasma levels of neuroleptics and thus indirectly influence the severity of TD.
2. The hyperkinetic dyskinesias might be mechani cally suppressed by an aggravation of rigidity after withdrawal of anticholinergic drugs. 3. Improvement of TD might be due to an increase in central cholinergic activity. (SIMPSON-ANGUS-scale) induced by the switch from biperiden to placebo (â€"p).
Pseudo-parkinsonism
The switch from biperiden to placebo resulted in an aggravation (more than two points on the Simpson-Angus scale) of pseudo-parkinsonism in three out of the ten patients; the mean values for all patients increased from 1.3 Â±1.2 on biperiden to 2.7 Â±2.4 on placebo (P <.05). Patient No. 10 had to be omitted from the study because she developed severe pseudo-parkinsonism, in the shape mainly of tremors, in the same topographical region in which she had exhibited dyskinesias before.
There was no relevant relationship between aggravation of pseudo-parkinsonism and improvement of TD (Figure 4 ).
The most impressive improvement was found in four patients who did not develop parkinsonian symptoms to a substantial degree. The patient with the greatest aggravation of pseudo-parkinsonism showed only a comparatively small improvement of TD. No significant negative correlation could be found between the severity of pseudo-parkinsonism and the severity of the BLM syndrome (Pearson's correlation coefficient; r = â€"¿ .22; n.s.).
Psychopathology
In seven patients, a worseningof theirmental statewas noted during the study period. In five cases, the deterioration of their mental state (mostly as depression and anxiety) seemed to be related in time to withdrawal of anticholinergic drugs.
Discussion
In ten patients with tardive dyskinesia who had been on long-term treatment with neuroleptic and anti cholinergic medication (bipenden), the anticholin ergic drug was discontinued under double-blind, placebo-controlled conditions; neuroleptic medication remained unchanged.
In accordance with previous investigations (Burnett et al, 1980; Reunanen et a!, 1982) No substantial support could be found either for the second hypothesis (suppression of TD by rigidity) in the present study, since there was no correlation between improvement of TD and aggravation of parkinsonism.
Hence, the best explanation seems to be that withdrawal of anticholinergic drugs leads to a reduc tion of TD by inducing a change in the central dopamine-acetylcholine interaction.
The number of patients in the present study is too small to analyse statistically the varying response of individual TD symptoms to withdrawal of anticholin ergic drugs. However, to sum up the findings of this and previous studies (Hippius & Logemann, 1970; Klawans & Rubovits, 1974; Sovner & DiMascio, 1977; Fann & Lake, 1974b ) the following dyskinesias could be classified as â€˜¿ dopaminergic' movements, in the sense that they are aggravated by dopaminergic and anticholinergic, and improved by antidopaminergic and cholinergic agents: Dyskinesias of the tongue and jaw, â€˜¿ piano-playing' movements of the fingers, rota tion/flexion movements of the ankles, dyskinesias of the toes, and hip-rocking. The pharmacological basis of the dyskinetic arm and leg movements (of a more athetoid character) remains unclear. Several authors have described a hyperkinetic syndrome which is improved by anticholinergic and worsened by cholin ergic drugs (Gerlach et a!, 1974; Casey & Denney, 1977; Moore & Bowers, 1980) , but this syndrome appears to be distinct from TD (Casey eta!, 1980) . Apart from their therapeutic effectiveness on park insonian symptoms, anticholinergic drugs are thought to have additional psychotropic (antidepressant) pro perties (Beckmann & Moises, 1982) . In the present study, deterioration of the mental state (depression, anxiety) in five patients seemed to be related in time to withdrawal of anticholinergic drugs. This assumption is based only on case records however, and no relevant statistical analysis could be done. Furthermore, the fact must be taken into consideration that psycho pathological deterioration following discontinuation of anticholinergic therapy can be interpreted, in part at least, as a reaction to increased parkinsonism (Manos, 1981; Jellinek, 1981 patients develop pseudo-parkinsonism to an extent which is more troublesome to the patient than was the previous TD. In the present study, only a few weeks after discontinuation, five out ofthe ten patients had to be put back on anticholinergic medication because of pseudo-parkinsonism; the other five patients, how ever, might have benefitted from withdrawal of anticholinergic drugs.
The difficult task of the clinician is to titrate treatment of the individual patient with TD so that he is least impaired by both movement disorders, TD, and pseudo-parkinsonism. However, in patients under combined treatment with neuroleptics and anticholin ergic drugs who are suffering from TD, the first therapeutic approach should be to try to discontinue anticholinergic medication.
